Version history

{
  "description": "Experiment challenge for hypothesis: Dual-Receptor Antibody Shuttling\n\n## Mechanistic Hypothesis\n## Mechanistic Overview\nDual-Receptor Antibody Shuttling starts from the claim that modulating not yet specified within the disease context of Alzheimer's disease can redirect a disease-relevant process. The original description reads: \"# Dual-Receptor Antibody Shuttling: A Strategic Approach to Overcoming Blood-Brain Barrier Limitations in Neurodegenerative Disease Therapy ## Overview The blood-brain barrier (BBB) represents the most significant obstacle to effective CNS therapeutics delivery, \n\n## Target Gene/Pathway\nNot specified\n\n## Disease Context\nAlzheimer's disease\n\n## Evidence Supporting this Hypothesis\n[{'pmid': '41194602', 'year': '2025', 'claim': 'Ketoboronate as a Minimal Covalent-Reversible Tag for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins.', 'source': 'J Am Chem Soc'}, {'pmid': '37823690', 'year': '2023', 'claim': 'Delivery of the Brainshuttle™ amyloid-beta antibod\n\n## Evidence Against / Caveats\n[{'pmid': '36257298', 'year': '2022', 'claim': 'Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.', 'source': 'paper', 'strength': '\n\n## Composite Score\n0.803 (mechanistic plausibility: 0.70, feasibility: 0.70, impact: 0.70, confidence: 0.45)\n",
  "challenge_type": "experimental_verification",
  "scope": "single_hypothesis",
  "initial_bounty_usd": 2046,
  "current_bounty_usd": 2046,
  "bounty_confidence": 0.8,
  "landscape_score": 0.7,
  "gap_importance_score": 1.4,
  "therapeutic_potential_score": 0.617,
  "market_price": 0.5,
  "composite_score": 0.803,
  "debate_count": 0,
  "status": "open",
  "question": "Dual-Receptor Antibody Shuttling",
  "domain": "Alzheimer's disease"
}